Novo Nordisk A/S (NYSE:NVO) Shares Sold by Cairn Investment Group Inc.

Cairn Investment Group Inc. lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 46.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,050 shares of the company's stock after selling 8,700 shares during the period. Cairn Investment Group Inc.'s holdings in Novo Nordisk A/S were worth $865,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of NVO. Strategic Investment Solutions Inc. IL bought a new position in shares of Novo Nordisk A/S during the second quarter worth $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S during the third quarter valued at $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S during the third quarter valued at $42,000. Albion Financial Group UT lifted its position in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after purchasing an additional 278 shares during the last quarter. Finally, Sound Income Strategies LLC lifted its position in Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after purchasing an additional 243 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 1.5 %

NVO stock traded up $1.30 during trading on Thursday, hitting $85.33. The company had a trading volume of 5,758,290 shares, compared to its average volume of 9,639,824. The firm has a market capitalization of $382.91 billion, a P/E ratio of 27.61, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a 50 day simple moving average of $94.32 and a 200-day simple moving average of $113.82. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Wall Street Analyst Weigh In

NVO has been the subject of several research reports. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research report on Monday, December 23rd. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Sunday, December 29th. Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Buy" and an average target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.